Status:

COMPLETED

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Hepatitis C, Chronic

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) vers...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Treatment naïve and treatment experienced patients (prior relapse, interferon intolerant, and \[allowed in Cohort A only\] prior partial response).
  • Chronic HCV infection of genotype 1 (GT1), sub-GT1b virus only.
  • Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver stiffness of =13 kPa on fibroscan.
  • Exclusion criteria:
  • HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-GT1a/1b or undefined diagnosed by genotypic testing at screening
  • Liver disease due to causes other than chronic HCV infection which may include but is not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases.
  • HIV infection
  • Patients who have been previously treated with an investigational or approved DAA

Exclusion

    Key Trial Info

    Start Date :

    April 1 2013

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2014

    Estimated Enrollment :

    35 Patients enrolled

    Trial Details

    Trial ID

    NCT01830127

    Start Date

    April 1 2013

    End Date

    October 1 2014

    Last Update

    November 20 2015

    Active Locations (19)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (19 locations)

    1

    1241.30.10003 Boehringer Ingelheim Investigational Site

    La Mesa, California, United States

    2

    1241.30.10007 Boehringer Ingelheim Investigational Site

    San Diego, California, United States

    3

    1241.30.10001 Boehringer Ingelheim Investigational Site

    DeLand, Florida, United States

    4

    1241.30.10012 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida, United States